Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ImmuCell Corporation (ICCC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ICCC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14
1 Year Target Price $14
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.94% | Avg. Invested days 28 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 60.73M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 1 | Beta 0.31 | 52 Weeks Range 3.34 - 7.60 | Updated Date 08/14/2025 |
52 Weeks Range 3.34 - 7.60 | Updated Date 08/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.04 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-14 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin -1% | Operating Margin (TTM) 13.85% |
Management Effectiveness
Return on Assets (TTM) 0.26% | Return on Equity (TTM) -1.01% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 69074001 | Price to Sales(TTM) 2.22 |
Enterprise Value 69074001 | Price to Sales(TTM) 2.22 | ||
Enterprise Value to Revenue 2.53 | Enterprise Value to EBITDA 23.48 | Shares Outstanding 9037400 | Shares Floating 6007971 |
Shares Outstanding 9037400 | Shares Floating 6007971 | ||
Percent Insiders 27.91 | Percent Institutions 20.26 |
Upturn AI SWOT
ImmuCell Corporation
Company Overview
History and Background
ImmuCell Corporation was founded in 1982. Initially focused on recombinant DNA technology for animal health, it has evolved to concentrate on preventing and treating diseases in young dairy and beef cattle, emphasizing natural colostrum-derived products.
Core Business Areas
- First Defenseu00ae: First Defense provides immediate immunity to newborn calves through antibodies derived from bovine colostrum. It is available in powder, bolus, and paste forms.
- Mast Outu00ae: Mast Out is a non-antibiotic intramammary treatment for mastitis in lactating dairy cows. It reduces the need for antibiotics by killing bacteria and stimulating immune response.
- Re-Tainu00ae: Re-Tain is a product intended to reduce the risk of retained placenta, a common post-calving issue in dairy cows.
Leadership and Structure
Michael F. Brigham serves as the President and CEO. The company has a board of directors overseeing strategic direction and corporate governance. The organizational structure consists of departments such as R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- First Defenseu00ae: A line of colostrum-derived antibody products providing passive immunity to newborn calves. Estimates place ImmuCell's market share for colostrum products in the US around 20-25%, competing with companies like Land O'Lakes Purina Feed LLC and Ralco Nutrition. No specific revenue data is publically available. First Defense is mainly competing with colostrum supplements and replacers.
- Mast Outu00ae: A non-antibiotic treatment for mastitis in lactating dairy cows. While market share data is not readily available, it competes with traditional antibiotic treatments (Pfizer, Merck) and other non-antibiotic alternatives for mastitis management. It is aimed at decreasing antibiotic resistance. No specific revenue data is publically available.
Market Dynamics
Industry Overview
The animal health market is experiencing growth, driven by increased livestock production, rising awareness of animal health, and growing demand for food safety. Demand for non-antibiotic treatments for livestock diseases is also growing in order to combat antimicrobial resistance.
Positioning
ImmuCell is positioned as a niche player within the animal health industry, focusing on preventing and treating diseases in young dairy and beef cattle using natural, colostrum-derived products and non-antibiotic solutions. This positions them well for consumers looking for natural means of combating infection in their livestock.
Total Addressable Market (TAM)
The global animal health market is estimated at over $50 billion. ImmuCell is focused on the mastitis and calf health segments, representing a portion of this TAM. It is well positioned for future growth.
Upturn SWOT Analysis
Strengths
- Specialized Focus on Dairy and Beef Cattle
- Proprietary Colostrum-Derived Products
- Non-Antibiotic Solutions for Mastitis
- Established Brand Recognition (First Defense)
- Strong relationships with Veterinary channels
Weaknesses
- Limited Product Portfolio
- Reliance on a Single Market (US)
- Small Market Cap Compared to Competitors
- Vulnerability to Colostrum Supply Fluctuations
- High Customer concentration
Opportunities
- Expanding Product Line (e.g., Re-Tain)
- Geographic Expansion (International Markets)
- Partnerships and Acquisitions
- Growth in Demand for Non-Antibiotic Treatments
- Growing direct to consumer market
Threats
- Competition from Larger Animal Health Companies
- Regulatory Changes Affecting Product Approvals
- Fluctuations in Colostrum Supply and Costs
- Economic Downturn Impacting Livestock Producers
- Emergence of New Diseases and Treatments
Competitors and Market Share
Key Competitors
- LLY
- MRK
- Zoetis Inc. (ZTS)
Competitive Landscape
ImmuCell faces intense competition from larger, more diversified animal health companies. Its competitive advantages lie in its specialized focus and proprietary colostrum-derived products. It's main disadvantage is less product diversification and less market visibility.
Growth Trajectory and Initiatives
Historical Growth: ImmuCell has experienced moderate revenue growth in recent years, driven by increased sales of First Defense and Mast Out. The rate of growth has fluctuated with changing market conditions.
Future Projections: Analyst estimates for ImmuCell's future growth vary. Expansion of the product line and geographic reach could contribute to growth.
Recent Initiatives: Recent initiatives include the launch of new products, expansion of manufacturing capacity, and strategic partnerships.
Summary
ImmuCell Corporation is a niche player in the animal health market specializing in colostrum-derived and non-antibiotic solutions for dairy and beef cattle. While it has established a solid position with products like First Defense, it faces competition from larger companies. The company needs to expand its product line and explore new markets to capitalize on the growing demand for preventative livestock health solutions. Overall the company is performing well within its segment with opportunities to continue expansion.
Peer Comparison
Sources and Disclaimers
Data Sources:
- ImmuCell Corporation Investor Relations
- SEC Filings
- Industry Reports
- Third Party Financial Data Providers
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ImmuCell Corporation
Exchange NASDAQ | Headquaters Portland, ME, United States | ||
IPO Launch date 1987-04-30 | President, CEO, Treasurer, Secretary & Director Mr. Michael F. Brigham | ||
Sector Healthcare | Industry Biotechnology | Full time employees 67 | Website https://immucell.com |
Full time employees 67 | Website https://immucell.com | ||
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.